Recent Updates
Recently added Catalysts
GERN Positive Sentiment Score: 70/100

Geron Plans to Present at Upcoming Investor Conferences

Monday, February 23, 2026 1 min read
Key Takeaway: Geron Corporation has announced that its management team will present at upcoming investor conferences. The company is focused on changing the course of blood cancer with its approved drug RYTELO® and is conducting a pivotal Phase 3 trial for imetelstat in specific hematologic malignancies. Archived webcasts of the presentations will be available on their website.

Market Sentiment Analysis

POSITIVE FACTORS

  • Geron is actively engaging with investors through presentations.
  • The company is advancing its first-in-class telomerase inhibitor, RYTELO®.
  • Geron is conducting a pivotal Phase 3 clinical trial, indicating progress in research.

Full Press Release Details

FOSTER CITY, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that members of the management team are scheduled to present at the following investor conferences:
A live and archived audio webcast of each fireside chat will be available through theInvestors & Mediasection of Geron’s website at www.geron.com.
About GeronGeron is a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer. Our first-in-class telomerase inhibitor RYTELO®(imetelstat) is approved in the United States and the European Union for the treatment of certain adult patients with LR-MDS with transfusion-dependent anemia. We are also conducting a pivotal Phase 3 clinical trial of imetelstat in JAK-inhibitor R/R MF, as well as studies in other hematologic malignancies. Inhibiting telomerase activity, which is increased in malignant stem and progenitor cells in the bone marrow, aims to potentially reduce proliferation and induce death of malignant cells. To learn more, visitwww.geron.comorLinkedIn.

Investors and MediaDawn SchottlandtSenior Vice President, Investor Relations and Corporate Affairsdschottlandt@geron.com

Frequently Asked Questions

What is Geron Corporation's focus?

Geron Corporation aims to change the course of blood cancer.

What is RYTELO® used for?

RYTELO® is approved for treating certain adult patients with LR-MDS.

What trial is Geron currently conducting?

Geron is conducting a pivotal Phase 3 clinical trial of imetelstat.

Where can I find the conference webcasts?

Webcasts of the presentations will be available on Geron's website.

Tags: GERN Viatris Investor Conferences Healthcare Geron Corporation RYTELO imetelstat blood cancer Phase 3 trial
Last updated: Feb 23, 2026